Serina Therapeutics, Inc. (SER)

Serina Therapeutics' stock price has been impacted by several events. In November 2025, the company reported its Third Quarter financial results. In January 2026, the FDA cleared the IND application for SER-252, leading to a stock price increase, but the company also received a NYSE American deficiency notification. In February 2026, the first patient was enrolled in the Phase 1 registrational trial for SER-252. In March 2026, Serina secured private placement financing, causing the stock to surge, and reported full-year 2025 financial results, showing a net loss and increased operating expenses, which led to a stock price decline. Insider selling activity was also reported in March 2026. In April 2026, NYSE American accepted Serina's plan for continued listing compliance. The stock has experienced significant volatility, with a decrease since January 1, 2026, and over the past year, and shareholder dilution has been identified as a major risk.

There is no information available regarding demand seasonality for Serina Therapeutics, Inc.'s products or services. As a clinical-stage biotechnology company, its primary product candidates are still in development and not yet commercially available, making traditional demand seasonality less applicable. The company's revenue has historically been derived from grant revenue.

Serina Therapeutics, Inc. is a clinical-stage biotechnology company focused on revolutionizing drug delivery systems using its POZ platform technology. The company operates in the Healthcare sector, specifically the Biotechnology industry, and aims to optimize drug delivery to improve therapeutic outcomes and patient quality of life. Serina is developing a pipeline of drug candidates for neurological diseases and pain, including SER-252 for advanced Parkinson's disease, SER-214 for early Parkinson's and Restless Leg Syndrome, SER-227 for long-acting pain relief, and SER-228 for epilepsy. The company also applies its POZ technology in RNA vaccines for infectious diseases.

Serina Therapeutics, Inc. is headquartered in Huntsville, Alabama, United States. The company has an operational presence in Australia due to a global registrational study for SER-252.

Serina Therapeutics' brand reputation has been influenced by clinical development progress, financial performance, and regulatory interactions. Positive impacts include the FDA clearance for SER-252 IND, initiation of the Phase 1b trial, securing financing, and acceptance of the NYSE compliance plan. Negative impacts include a prior clinical hold on SER-252, financial performance and NYSE deficiency, shareholder dilution, and insider selling.

Serina Therapeutics, Inc. has a mixed ownership structure including institutional, retail, and individual investors. Institutional investors own approximately 1.61% to 3.02% of the stock, with major holders including Vanguard Group Inc and BlackRock, Inc. Public companies and retail investors own approximately 95.11% of the stock. Insiders own approximately 1.87% of the stock, with negative sentiment due to open-market selling from key executives.